Bright Minds Biosciences Inc.: financial statements

DRUGNASDAQHealthcare · Pharmaceutical Preparations

Price

$20.40

November 20, 2026Market cap $140M

What Ploutos Investor adds for Bright Minds Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from FY2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2023–FY2025 fiscal years

Click a line to see it on the chart.

Net income

LineFY2023FY2024FY2025Average a year
Net income -$5.4M-$2.1M-$8.8M
Earnings per share -$1.46-$0.48–
Earnings per share, basic -$1.46-$0.48-$1.28

Financial statements

DRUG's revenue, profits and cash flows from FY2020 to FY2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Bright Minds Biosciences's filings show?

These are Bright Minds Biosciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about DRUG's financials

Didn't find what you were looking for?

Ask us
How much debt does DRUG have?

On September 30, 2025 Bright Minds Biosciences had total assets of $61M, debt of – and shareholders' equity of $59M.

Where are the figures from?

From Bright Minds Biosciences Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.